Accelerate Diagnostics, Inc. (AXDX) Director Buys $955,549.27 in Stock

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Director Jack W. Schuler acquired 51,181 shares of the stock in a transaction dated Friday, November 10th. The stock was acquired at an average price of $18.67 per share, for a total transaction of $955,549.27. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Accelerate Diagnostics, Inc. (NASDAQ AXDX) traded up $0.40 during trading hours on Tuesday, hitting $19.15. 302,700 shares of the company traded hands, compared to its average volume of 332,269. Accelerate Diagnostics, Inc. has a twelve month low of $16.75 and a twelve month high of $30.45.

ILLEGAL ACTIVITY WARNING: “Accelerate Diagnostics, Inc. (AXDX) Director Buys $955,549.27 in Stock” was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.chaffeybreeze.com/2017/11/14/accelerate-diagnostics-inc-axdx-director-buys-955549-27-in-stock.html.

Several large investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc grew its stake in shares of Accelerate Diagnostics by 0.3% in the first quarter. Legal & General Group Plc now owns 5,123 shares of the medical research company’s stock valued at $123,000 after buying an additional 15 shares in the last quarter. Geneva Advisors LLC grew its stake in shares of Accelerate Diagnostics by 0.5% in the second quarter. Geneva Advisors LLC now owns 48,899 shares of the medical research company’s stock valued at $1,337,000 after buying an additional 238 shares in the last quarter. Parametric Portfolio Associates LLC grew its stake in shares of Accelerate Diagnostics by 2.2% in the second quarter. Parametric Portfolio Associates LLC now owns 22,966 shares of the medical research company’s stock valued at $628,000 after buying an additional 492 shares in the last quarter. Obermeyer Wood Investment Counsel Lllp grew its stake in shares of Accelerate Diagnostics by 0.3% in the second quarter. Obermeyer Wood Investment Counsel Lllp now owns 213,367 shares of the medical research company’s stock valued at $5,836,000 after buying an additional 660 shares in the last quarter. Finally, California State Teachers Retirement System grew its stake in shares of Accelerate Diagnostics by 1.5% in the second quarter. California State Teachers Retirement System now owns 46,111 shares of the medical research company’s stock valued at $1,261,000 after buying an additional 700 shares in the last quarter. 44.44% of the stock is owned by institutional investors and hedge funds.

AXDX has been the topic of a number of recent research reports. BidaskClub downgraded shares of Accelerate Diagnostics from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. Zacks Investment Research downgraded shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. Finally, ValuEngine cut shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Three research analysts have rated the stock with a sell rating and two have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $33.00.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.

Insider Buying and Selling by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply